

GENETIC SUMMARY

DEMO

Sex	Male	Report date	2016-11-21
Ethnicity	Caucasian	Specimen	Saliva
Date of birth	1970-07-25	Sample number	BIO-999-99999

GENES

ACTIVITY LEVELS

CYP2C19	Increased
CYP2C9	Normal
CYP2D6	Normal
CYP3A5	Reduced
DPYD	Reduced
NAT2	Reduced
SLCO1B1	Normal
TPMT	Normal
VKORC1	Normal

Signature: *Thomas Maher 2016-081* 2016-11-21

PHARMACOGENETIC SUMMARY

INCREASED RISK OF ADVERSE DRUG REACTIONS

5-Fluorouracil Capecitabine

INEFFICIENT THERAPEUTIC RESPONSE EXPECTED

Amitriptyline	Citalopram	Clomipramine	Doxepin
Escitalopram	Esomeprazole	Imipramine	Lansoprazole
Omeprazole	Pantoprazole	Sertraline	Trimipramine

NORMAL RESPONSE EXPECTED

Acenocoumarol	Aripiprazole	Atomoxetine	Azathioprine
Carvedilol	Celecoxib	Cisplatin	Clobazam
Clopidogrel	Codeine	Desipramine	Diazepam
Duloxetine	Flecainide	Fluoxetine	Flurbiprofen
Fluvoxamine	Galantamine	Haloperidol	Isoniazid
Mercaptopurine	Metoprolol	Mirtazapine	Nortriptyline
Oxycodone	Paroxetine	Perphenazine	Phenytoin
Pimozide	Propafenone	Risperidone	Simvastatin
Tacrolimus	Tamoxifen	Tetrabenazine	Thioguanine
Tolterodine	Tramadol	Venlafaxine	Voriconazole
Vortioxetine	Warfarin	Zuclopenthixol	

Amitriptyline

Psychiatry & Neurology

Elavil®, Levate®, Trilavil®

NOTIFICATION

Increased probability of treatment failure with standard dosing of amitriptyline

RECOMMENDATION

DRUG USAGE

Your body may metabolize and eliminate amitriptyline at a faster rate than expected.

depression, neuropathic pain

- Be alert to insufficient response.
- The use of an alternative medication could improve your treatment.
- Consult your healthcare provider to optimize your therapy.

GENE

GENOTYPE

PHENOTYPE

CYP2D6

*1/*2A

normal activity

CYP2C19

*1/*17

ultrarapid activity

Citalopram

Celexa®

Psychiatry & Neurology

NOTIFICATION

Increased probability of treatment failure with standard dosing of citalopram

RECOMMENDATION

Your body may metabolize and eliminate citalopram at a faster rate than expected.

- The use of an alternative medication could improve treatment efficacy.
- Consult your healthcare provider to optimize your therapy.

DRUG USAGE

depression

GENE

GENOTYPE

PHENOTYPE

CYP2C19

*1/*17

ultrarapid activity

Nortriptyline

Psychiatry & Neurology

Aventyl®

NOTIFICATION

No genetic variation identified that would prompt changes to nortriptyline therapy

RECOMMENDATION

Your body should metabolize and eliminate nortriptyline normally. Therefore, a standard dose of this medication should be safe and efficient.

- No change to the recommended dose.

DRUG USAGE

depression, neuropathic pain

GENE

GENOTYPE

PHENOTYPE

CYP2D6

*1/*2A

normal activity

Paroxetine

Psychiatry & Neurology

Paxil®

NOTIFICATION

No genetic variation identified that would prompt changes to paroxetine therapy

RECOMMENDATION

DRUG USAGE

Your body should metabolize and eliminate paroxetine normally. Therefore, a standard dose of this medication should be safe and efficient.

depression

- No change to the recommended dose.

GENE

GENOTYPE

PHENOTYPE

CYP2D6

*1/*2A

normal activity

5-Fluorouracil

5-FU®

NOTIFICATION

Increased risk of adverse drug reactions with standard dosing of 5-fluorouracil

RECOMMENDATION

Your body may metabolize and eliminate 5-fluorouracil at a slower rate than expected.

- Be alert to adverse drug reactions (e.g. neutropenia, nausea, vomiting, severe diarrhea, stomatitis, mucositis, hand-foot syndrome, and neuropathy).
- A dose adjustment could improve your treatment.
- Consult your healthcare provider to optimize your therapy.

DRUG USAGE

various cancers

GENE

GENOTYPE

PHENOTYPE

DPYD

*1/*2A

reduced activity

Capecitabine

Xeloda®

Cancer & Immunology

NOTIFICATION

Increased risk of adverse drug reactions with standard dosing of capecitabine

RECOMMENDATION

Your body may metabolize and eliminate capecitabine at a slower rate than expected.

- Be alert to adverse drug reactions (e.g. neutropenia, nausea, vomiting, severe diarrhea, stomatitis, mucositis, hand-foot syndrome, and neuropathy).
- A dose adjustment could improve your treatment.
- Consult your healthcare provider to optimize your therapy.

DRUG USAGE

various cancers

GENE

GENOTYPE

PHENOTYPE

DPYD

*1/*2A

reduced activity